Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
174,282,170
-
Total 13F shares
-
20,015,632
-
Share change
-
+6,009,297
-
Total reported value
-
$69,461,479
-
Price per share
-
$3.47
-
Number of holders
-
72
-
Value change
-
+$20,027,239
-
Number of buys
-
41
-
Number of sells
-
19
Institutional Holders of Prime Medicine, Inc. - COMMON STOCK (PRME) as of Q4 2025
As of 31 Dec 2025,
Prime Medicine, Inc. - COMMON STOCK (PRME) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,015,632 shares.
The largest 10 holders included
VANGUARD GROUP INC, ARK Investment Management LLC, Sumitomo Mitsui Trust Group, Inc., Amova Asset Management Americas, Inc., GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, GOLDMAN SACHS GROUP INC, Greenwich Wealth Management LLC, JPMORGAN CHASE & CO, and HighTower Advisors, LLC.
This page lists
75
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.